Definium Therapeutics Achieves Historic Phase 3 Milestone with LSD-Based Depression Treatment

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company, announced positive topline results from its Phase 3 Emerge study on June 22, 2026. The trial evaluated DT120, a proprietary orally disintegrating tablet formulation of lysergide (LSD), in adults with major depressive disorder (MDD). Notably, the study met its primary endpoint and every key secondary efficacy endpoint. Shares surged roughly 53% on the news. This marks the first successful Phase 3 readout for an LSD-based therapy in history.

Understanding the Scale of the MDD Treatment Gap

Major depressive disorder affects more than 21 million adults in the United States each year. It is a leading cause of disability worldwide and carries a $326 billion annual economic burden driven by healthcare costs and lost productivity. Despite decades of pharmacological development, the treatment landscape remains deeply inadequate. Fewer than one-third of patients reach remission with first-line therapies. Beyond that, many who do respond experience a slow onset of relief that takes weeks to materialize, tolerability problems that prompt discontinuation, and a revolving cycle of medication switching. In short, the existing standard of care leaves the majority of MDD patients without a satisfying answer.

Trial Design and the Mechanics of DT120

The Emerge study was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. It enrolled 149 adults aged 18 to 74 across 20 clinical sites. Participants were required to have a DSM-5-confirmed MDD diagnosis, a baseline MADRS score of at least 26, and a CGI-S severity rating of at least 4. Each participant received a single 100 microgram dose of DT120 ODT or placebo. The 12-week blinded phase was then followed by a 40-week open-label extension in which patients could receive additional doses based on symptom severity. DT120 itself is built on Catalent’s Zydis fast-dissolve technology, which enables rapid absorption, improved bioavailability, and a lower rate of gastrointestinal side effects compared to conventional oral formulations. As a partial agonist of the serotonin 5-HT2A receptor, the compound acts on the same neurochemical pathway implicated in neuroplasticity and mood regulation.

Efficacy Data That Outpaces the Competitive Landscape

The primary endpoint was the change from baseline in MADRS total score at Week 6. DT120-treated patients recorded a mean reduction of 13.3 points, versus 5.2 points for placebo—a placebo-adjusted difference of 8.1 points (p<0.0001). That figure is particularly striking in context. According to Definium’s own comparative analysis, the 8.1-point placebo-adjusted reduction exceeded the performance of approved antidepressants such as Takeda’s Trintellix and Axsome Therapeutics’ Auvelity, as well as the investigational psilocybin therapy from Compass Pathways. The second-closest benchmark was Johnson & Johnson’s ketamine-based nasal spray Spravato, at 6.8 points. Direct cross-trial comparisons are inherently limited by differences in methodology and patient populations, but the margin is nonetheless meaningful.

Beyond the primary endpoint, the speed and durability of the effect were equally notable. At Week 1—just seven days after a single dose—patients showed a placebo-adjusted MADRS reduction of 14.2 points (p<0.0001). The effect held at Week 12 with a 7.3-point reduction (p<0.0001). Response rates (a 50% or greater improvement in MADRS score) were 35% for DT120 versus 7% for placebo at Week 6. Remission rates (MADRS score at or below 12) were 24% versus 3%, respectively. Stifel analysts noted that the results exceeded expectations with clear and robust efficacy.

Safety Profile and Day-of-Dosing Tolerability

One of the most commercially relevant questions surrounding any psychedelic-derived therapy is whether the day-of-dosing experience can be safely managed in a clinical setting. On that front, Emerge delivered reassuring data. Ninety-nine percent of treatment-emergent adverse events were mild to moderate in severity, transient, and concentrated on the day of dosing itself. No serious adverse events were reported. Crucially, no increase in suicidal ideation or behavior was observed—a safety signal that regulators closely scrutinize in any antidepressant program. Discontinuation rates were low and comparable between the two groups.

The trial also used a structured end-of-session checklist, assessed hourly from hours 5 to 8 on dosing day. The average time to meeting discharge criteria was 5.8 hours, with a median of 5.1 hours. Importantly, 100% of participants met the criteria by the eighth hour. That consistency in session duration matters enormously for operational planning, since healthcare systems evaluating DT120 will need to build a reliable scheduling model around the day-of-dosing window.

Regulatory Pathway and the Pipeline Beyond MDD

Emerge is one of two pivotal Phase 3 studies Definium is running in MDD. The second trial, called Ascend, incorporates a lower-dose arm alongside the 100 microgram cohort, a design element intended to address functional unblinding concerns that regulators have raised with psychedelic trials more broadly. Results from Ascend are expected later this year. CEO Rob Barrow stated the company plans to have additional data in hand before initiating formal FDA submission discussions, though approval would likely initially target treatment-resistant patients who have failed at least two prior antidepressants.

The regulatory environment has also shifted favorably. The FDA granted DT120 Breakthrough Therapy designation for generalized anxiety disorder. Furthermore, former Commissioner Marty Makary and the broader current administration have signaled a priority posture toward psychedelic mental health therapies. Definium itself is investigating DT120 across multiple indications: in addition to MDD and GAD, the company is running Phase 3 studies in PTSD, and it holds a separate MDMA program targeting autism spectrum disorder. As a result, a successful FDA submission for MDD would serve as the commercial anchor for a significantly broader neuropsychiatric franchise.

Strategic Investment Summary

• Historic Milestone: Definium Therapeutics (NASDAQ: DFTX) reported positive topline results from the Phase 3 Emerge trial on June 22, 2026, the first successful Phase 3 readout for an LSD-based therapy in clinical history.
• Primary Endpoint: A single 100 μg dose of DT120 ODT produced an 8.1-point placebo-adjusted reduction in MADRS total score at Week 6 (p<0.0001), meeting the primary endpoint with high statistical significance.
• Speed and Durability: The treatment delivered a 14.2-point placebo-adjusted MADRS reduction as early as Week 1, and maintained a 7.3-point reduction through Week 12—all from a single dose.
• Competitive Edge: DT120’s 8.1-point placebo-adjusted effect size outpaced benchmarks for approved antidepressants including Trintellix, Auvelity, and Spravato, as well as Compass Pathways’ investigational psilocybin therapy.
• Safety Signal: The drug was generally well tolerated, with 99% of adverse events mild to moderate and no serious events, no suicidality signal, and 100% of patients meeting structured discharge criteria within eight hours of dosing.
• Pipeline Depth: A second pivotal MDD trial (Ascend) is ongoing, alongside Phase 3 programs in GAD and PTSD, positioning DT120 as the potential cornerstone of a broad neuropsychiatric franchise.
• Regulatory Tailwinds: DT120 holds FDA Breakthrough Therapy designation for GAD, and the current regulatory environment has prioritized psychedelic-based mental health therapies, strengthening the path to approval.

Find out more about the latest clinical data and financial reports at the Definium Therapeutics investor portal.